Rate of Change of HbA1c (dx/dt) May Predict Progression to Type 2 DM: Comparing the Concept of dx/dt With QD Diabetes Prediction Model. D.E.R.M.S Initiative (Doctor Enabled Risk Management System)

Wyckoff Heights Medical Center1 site in 1 country542 target enrollmentMarch 2011

ConditionsDiabetes Mellitus Type 2

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Diabetes Mellitus Type 2
Sponsor: Wyckoff Heights Medical Center
Enrollment: 542
Locations: 1
Primary Endpoint: Study the rate of change of HbA1c in normal population with known risk factors of diabetes
Status: Terminated
Last Updated: 14 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The investigators hypothesize that the HbA1c shows a rising trend in pre-diabetics and normal population with risk factors of developing type 2 DM. There is no known diabetes model for predicting incident diabetes in an individual which takes into account the rate of change of HbA1c (dx/dt). In such cases, the rate of change of HbA1c may give the physicians lead time needed to implement the Diabetes Prevention Program measures.

Registry

clinicaltrials.gov

Start Date

March 2011

End Date

September 2012

Last Updated

14 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Wyckoff Heights Medical Center

Eligibility Criteria

Inclusion Criteria

•No self-reported history of diabetes or pre-diabetes defined as per ADA criteria
•Age greater than 18 years
•Scheduled to receive HbA1c in participating clinic
•Able and willing to give legally effective consent
•Able and willing to participate in patient questionnaires(attached)

Exclusion Criteria

•Previously or currently taking medications for lowering glucose (i.e., exenatide, pramlintide, metformin, rosiglitazone, pioglitazone, or future diabetes drugs) based on self-report and/or prescreening. Patients on drugs causing hyperglycemia like Oral Steroids will be excluded.
•Baseline HbA1c level above 5.7
•Severe Anemia (defined as Hb less than 8gm/dL)
•Patients with hemoglobinopathies
•Pregnancy
•Polycystic ovarian disease